4/24
04:05 am
afmd
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Medium
Report
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
4/1
12:17 pm
afmd
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
High
Report
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
4/1
12:17 pm
afmd
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $30.00 to $25.00. They now have an "overweight" rating on the stock.
High
Report
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $30.00 to $25.00. They now have an "overweight" rating on the stock.
4/1
11:03 am
afmd
Affimed (NASDAQ: AFMD) had its price target raised by analysts at Stifel Nicolaus from $1.00 to $5.00. They now have a "hold" rating on the stock.
High
Report
Affimed (NASDAQ: AFMD) had its price target raised by analysts at Stifel Nicolaus from $1.00 to $5.00. They now have a "hold" rating on the stock.
4/1
08:09 am
afmd
Affimed (NASDAQ: AFMD) had its price target raised by analysts at HC Wainwright to $10.00. They now have a "buy" rating on the stock.
High
Report
Affimed (NASDAQ: AFMD) had its price target raised by analysts at HC Wainwright to $10.00. They now have a "buy" rating on the stock.
3/28
06:30 am
afmd
Affimed Reports 2023 Financial Results and Operational Progress
Medium
Report
Affimed Reports 2023 Financial Results and Operational Progress
3/21
06:30 am
afmd
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
Medium
Report
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
3/6
06:30 am
afmd
Affimed Announces 1-for-10 Reverse Stock Split
Medium
Report
Affimed Announces 1-for-10 Reverse Stock Split